Regulatory Celcuity gains FDA approval for closely watched breast cancer drug BioPharma DiveStill, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk.OncologyRead full story pharminent July 15, 2026 (Last updated: July 20, 2026) BioPharma Dive Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Oncology Read full story Post navigation Previous: AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drugNext: J&J Streamlines Pharma Supply Chain Amid $55B US Manufacturing Push Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026